SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the exclusive worldwide license agreement with Sanofi announced on August 1, 2024, has closed following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The agreement provides Vir with an exclusive worldwide license to three clinical-stage masked T-cell engagers (TCEs) with potential applications in a range of cancers and exclusive use of the proprietary PRO-XTENTM masking platform for oncology and infectious disease.

旧金山--（商业新闻短讯）--Vir Biotechnology，Inc.（纳斯达克：Vir）今天宣布，2024年8月1日宣布的与赛诺菲的独家全球许可协议在1976年哈特·斯科特·罗迪诺反托拉斯改进法案规定的等待期届满后终止。该协议为Vir提供了三个临床阶段掩蔽T细胞参与者（TCE）的全球独家许可，这些参与者可能在一系列癌症中应用，并独家使用专有的PRO-XTENTM掩蔽平台用于肿瘤学和传染病。

Key employees from Sanofi with extensive scientific and development expertise in TCEs, and in-depth experience using the PRO-XTEN platform, will join Vir. Further information about the TCEs and their respective development plans will be provided at Vir’s upcoming R&D Day in November..

赛诺菲的关键员工将加入Vir，他们在TCE领域拥有广泛的科学和开发专业知识，并拥有使用PRO-XTEN平台的深入经验。有关TCE及其各自发展计划的更多信息将在11月即将到来的Vir研发日上提供。。

“The closing of this strategic agreement with Sanofi is a pivotal moment for Vir and a significant opportunity to help address patient unmet needs. We are excited to further advance the masked T-cell engagers in clinical development, bolstering our clinical pipeline and adding near-term value creation opportunities,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer.

“与赛诺菲达成战略协议对维尔来说是一个关键时刻，也是帮助满足患者未满足需求的重要机会。我们很高兴能进一步推进掩蔽 T 细胞吞噬剂的临床开发，加强我们的临床管线，增加近期创造价值的机会，"Vir 首席执行官、理学硕士、博士、工商管理硕士 Marianne De Backer 说。

“Our proven expertise in antibody engineering and clinical development combined with the innovative PRO-XTEN masking platform offers a unique opportunity to discover and develop therapies in oncology and infectious disease.”.

“我们在抗体工程和临床开发方面的成熟专业知识与创新的PRO-XTEN掩蔽平台相结合，为发现和开发肿瘤学和传染病疗法提供了独特的机会。”。

The clinical-stage assets Vir is licensing under the agreement are:

根据协议，Vir 将授权使用的临床阶段资产包括

SAR446309 is a dual-masked HER2-targeted TCE in phase 1 clinical study including participants with metastatic treatment resistant HER2+ tumors such as breast and colorectal cancers.

SAR446309是一项针对HER2的双重掩蔽TCE，用于1期临床研究，包括患有转移性治疗耐药HER2+肿瘤（如乳腺癌和结直肠癌）的参与者。

SAR446329 is a dual-masked PSMA-targeted TCE in phase 1 clinical study including participants with metastatic castration-resistant prostate cancer.

SAR446329是一项双掩蔽PSMA靶向TCE的1期临床研究，包括转移性去势抵抗性前列腺癌的参与者。

SAR446368 is a dual-masked EGFR targeted TCE with an active IND. A phase 1 clinical study, which is expected to begin enrollment in the first quarter of 2025, will include participants with EGFR-expressing tumors of various types.

SAR446368是一种双重掩蔽的EGFR靶向TCE，具有活跃的IND。一项预计于2025年第一季度开始注册的1期临床研究将包括表达EGFR的各种类型肿瘤的参与者。

About the PRO-XTENTM Masking Platform

关于PRO-XTENTM掩蔽平台

The PRO-XTEN proprietary masking platform can be applied to TCEs, cytokines, and other molecules potentially broadening the therapeutic index (TI) for patients. This technology exploits the high protease activity of the tumor microenvironment (TME) to specifically activate (unmask) drug candidates in tumor tissues.

PRO-XTEN专有掩蔽平台可应用于TCE，细胞因子和其他可能扩大患者治疗指数（TI）的分子。该技术利用肿瘤微环境（TME）的高蛋白酶活性来特异性激活（揭露）肿瘤组织中的候选药物。

The selective cleavage results in the active molecule being released preferentially in the TME, potentially increasing the TI by minimizing off-target activity and toxicity associated with the systemic immune activation seen with traditional TCEs. Vir has exclusively licensed the PRO-XTEN proprietary masking platform from Sanofi in the fields of oncology and infectious diseases..

选择性切割导致活性分子优先在TME中释放，通过最小化与传统TCE所见的全身免疫激活相关的脱靶活性和毒性，可能增加TI。Vir在肿瘤学和传染病领域独家授权赛诺菲的PRO-XTEN专有掩蔽平台。。

About Vir Biotechnology, Inc.

关于Vir Biotechnology，Inc。

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir’s clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs.

Vir Biotechnology，Inc.是一家临床阶段的生物制药公司，专注于通过发现和开发治疗严重传染病和癌症的药物来增强免疫系统以改变生活。Vir的临床阶段投资组合包括针对慢性三角型肝炎和慢性乙型肝炎感染的传染病计划，以及多种肿瘤学计划。

Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir routinely posts information that may be important to investors on its website..

Vir还拥有一系列其他传染病和恶性肿瘤的临床前项目组合。Vir定期在其网站上发布对投资者可能很重要的信息。